Aquestive Therapeutics/$AQST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
- Ticker
- $AQST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 147
- Headquarters
- Warren, United States
- Website
- www.aquestive.com
AQST Metrics
BasicAdvanced
$460M
-
-$0.64
1.50
-
Price and volume
Market cap
$460M
Beta
1.5
52-week high
$6.85
52-week low
$2.93
Average daily volume
2.2M
Financial strength
Current ratio
6.117
Quick ratio
5.527
Long term debt to equity
-0.821
Total debt to equity
-0.83
Interest coverage (TTM)
-3.73%
Profitability
EBITDA (TTM)
-55.174
Gross margin (TTM)
65.34%
Net profit margin (TTM)
-162.33%
Operating margin (TTM)
-114.12%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-24.63%
Return on equity (TTM)
211.59%
Valuation
Price to revenue (TTM)
9.28
Price to book
-6.5
Price to tangible book (TTM)
-6.5
Price to free cash flow (TTM)
-11.137
Free cash flow yield (TTM)
-8.98%
Free cash flow per share (TTM)
-0.329
Growth
Revenue change (TTM)
12.54%
Earnings per share change (TTM)
-7.93%
3-year revenue growth (CAGR)
0.54%
3-year earnings per share growth (CAGR)
44.98%
What the Analysts think about AQST
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
Analyst projections of the future price of Aquestive Therapeutics stock.
Bulls say / Bears say
Aquestive says its September NDA resubmission includes improved use testing: median pouch-opening time fell from 17 seconds to 3, and incorrect placement fell from 20 participants to two. This directly addresses the human-factors issues behind the FDA’s January rejection. (GlobeNewswire)
Anaphylm’s pocket-sized, needle-free film could offer an easier-to-carry alternative to auto-injectors for people who need emergency epinephrine. That gives the product a distinct proposition if it wins approval and gains acceptance among patients and clinicians. (GlobeNewswire)
AQST-108 offers an early source of pipeline optionality beyond Anaphylm: a Phase 1 study reported no drug-related adverse events and a signal on a biomarker relevant to inflammation. The findings are preliminary, but support further study in conditions such as atopic dermatitis. (GlobeNewswire)
Anaphylm remains unapproved after an FDA rejection, and the agency must still assess whether the resubmission resolves its concerns. The FDA could request further information or studies, and the review could take longer than the company hopes. (PharmaDeviceNews)
A convenient format does not guarantee commercial success: the company still needs payer coverage and prescriber and patient uptake in a market shaped by established auto-injectors. Management has acknowledged that securing payer coverage takes time and that launch execution will be important. (Investing.com)
Aquestive’s cash may be pressured before a new product reaches market: it reported $98.5 million in cash at June-end, alongside $24.2 million of operating cash use and $51.9 million in royalty obligations. Its 2026 guidance still calls for a $30 million to $35 million adjusted EBITDA loss. (StockTitan, SEC)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
AQST Financial Performance
Revenues and expenses
AQST Earnings Performance
Company profitability
Upcoming events
No upcoming events
AQST News
AllArticlesVideos
Funds containing AQST
Fund name | Fund size | $AQST weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.